Israel Englander Acelrx Pharmaceuticals Inc Transaction History

Millennium Management LLC

  • $207 Billion
  • Q2 2024

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.2 - $0.35 $39,404 - $68,957
197,022 New
197,022 $41,000
Q2 2022

Aug 15, 2022
SELL
$0.18 - $0.29 $15,337 - $24,710
-85,210 Closed
0 $0
Q1 2022

May 16, 2022
SELL
$0.28 - $0.61 $69,730 - $151,913
-249,038 Reduced 74.51%
85,210 $24,000
Q4 2021

Feb 14, 2022
BUY
$0.49 - $1.02 $46,900 - $97,630
95,716 Added 40.13%
334,248 $187,000
Q3 2021

Nov 15, 2021
SELL
$0.93 - $1.51 $1.19 Million - $1.93 Million
-1,278,183 Reduced 84.27%
238,532 $243,000
Q2 2021

Aug 16, 2021
BUY
$1.03 - $1.7 $281,163 - $464,055
272,974 Added 21.95%
1,516,715 $2.09 Million
Q1 2021

May 17, 2021
BUY
$1.25 - $2.77 $1.37 Million - $3.03 Million
1,094,352 Added 732.55%
1,243,741 $2.11 Million
Q4 2020

Feb 16, 2021
SELL
$1.18 - $1.98 $38,164 - $64,039
-32,343 Reduced 17.8%
149,389 $185,000
Q3 2020

Nov 16, 2020
BUY
$1.01 - $1.81 $183,549 - $328,934
181,732 New
181,732 $258,000
Q2 2020

Aug 14, 2020
SELL
$1.03 - $1.69 $15,637 - $25,657
-15,182 Closed
0 $0
Q1 2020

May 14, 2020
SELL
$0.76 - $2.07 $27,786 - $75,681
-36,561 Reduced 70.66%
15,182 $18,000
Q4 2019

Feb 14, 2020
SELL
$1.66 - $2.4 $187,158 - $270,590
-112,746 Reduced 68.54%
51,743 $109,000
Q3 2019

Nov 14, 2019
BUY
$2.1 - $2.87 $83,309 - $113,855
39,671 Added 31.78%
164,489 $361,000
Q2 2019

Aug 15, 2019
SELL
$2.1 - $3.93 $4.8 Million - $8.98 Million
-2,284,097 Reduced 94.82%
124,818 $316,000
Q2 2019

Aug 14, 2019
BUY
$2.1 - $3.93 $3.23 Million - $6.04 Million
1,537,506 Added 176.44%
2,408,915 $43.9 Million
Q1 2019

May 14, 2019
BUY
$2.35 - $3.83 $1.89 Million - $3.07 Million
802,426 Added 1163.22%
871,409 $3.03 Million
Q4 2018

Feb 14, 2019
BUY
$2.13 - $4.8 $146,933 - $331,118
68,983 New
68,983 $159,000
Q2 2018

Aug 14, 2018
SELL
$2.13 - $4.2 $490,042 - $966,281
-230,067 Closed
0 $0
Q1 2018

May 15, 2018
SELL
$1.7 - $2.35 $211,247 - $292,018
-124,263 Reduced 35.07%
230,067 $483,000
Q4 2017

Feb 14, 2018
SELL
$1.75 - $5.5 $133,061 - $418,192
-76,035 Reduced 17.67%
354,330 $718,000
Q3 2017

Nov 14, 2017
BUY
$2.9 - $4.6 $1.25 Million - $1.98 Million
430,365
430,365 $1.98 Million

About ACELRX PHARMACEUTICALS INC

ACRX Quotes by TradingView
  • Ticker ACRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 7,366,600
  • Market Cap $8.32M
  • Description
  • AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...
More about ACRX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email